TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
EXEL

Exelixis Inc

Healthcare · Biotechnology

58.20$ +0.4% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement EXEL
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
8.1% 10.5% 3.4% 3.3% 3.1% 3.4% 3.7% 3.7% 3.6% 4.0% 3.5% 3.6%
91.9% 89.5% 96.6% 96.7% 96.9% 96.6% 96.3% 96.3% 96.4% 96.0% 96.5% 96.4%
753.1% 259.2% 50.1% 24.8% 21.3% 34.8% 55.5% 48.3% 55.4% 57.0% 42.0% 35.6%
202.4% 154.2% 60.7% 35.2% 24.2% 23.6% 29.7% 28.0% 28.5% 27.5% 22.7% 20.1%
955.5% 413.4% 110.8% 60.0% 45.5% 58.4% 85.2% 76.3% 83.9% 86.7% 68.6% 58.8%
-893.9% -326.6% -14.7% 36.7% 51.4% 38.2% 11.1% 20.0% 12.5% 9.3% 27.9% 37.6%
164.7% 109.4% 17.3% 1.9% 0.0% 0.0% 0.0% 0.0% 3.3% – – –
-1,070.1% -456.5% -36.7% 35.0% 52.9% 41.1% 13.2% 20.5% 14.5% 14.1% 31.4% 40.6%
-0.7% 0.1% 16.7% 1.0% -27.9% 8.0% 1.9% 4.4% 3.2% 2.7% 7.4% 6.8%
-1,069.4% -456.6% -36.7% 34.1% 80.8% 33.2% 11.3% 16.1% 11.3% 11.4% 24.0% 33.7%
-846.3% -322.7% -11.7% 37.0% 52.9% 39.0% 12.1% 20.9% 13.8% 15.5% 33.1% 39.7%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?